Journal
FRONTIERS IN CARDIOVASCULAR MEDICINE
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcvm.2021.701279
Keywords
rs7903146; metabolism; atherosclerosis; CVD
Categories
Funding
- Natural Science Foundation of China [82170485]
- Natural Science Foundation of Hunan Province, China [2019JJ40249]
- Outstanding Young Aid Program for Education Department of Human Province [18B274]
- Major Project of social science achievement review committee in Hunan Province [XSP20ZDI013]
- Key Project of Hunan Provincial Department of Education [20A427]
- Graduate Research innovation Project of School of Nursing, University of South China [2021CX22]
Ask authors/readers for more resources
TCF7L2, a crucial member of the TCF/LEF family, exerts various anti-atherosclerotic effects through specific molecular mechanisms, with rs7903146 serving as a genetic high-risk factor for type 2 diabetes and linking metabolic disorders to cardiovascular diseases.
Transcription factor-7-like-2 (TCF7L2), a vital member of the T-cell factor/lymphoid enhancer factor (TCF/LEF) family, plays an important role in normal human physiological and pathological processes. TCF7L2 exhibits multiple anti-atherosclerotic effects through the activation of specific molecular mechanisms, including regulation of metabolic homeostasis, macrophage polarization, and neointimal hyperplasia. A single-nucleotide substitution of TCF7L2, rs7903146, is a genetic high-risk factor for type 2 diabetes and indicates susceptibility to cardiovascular disease as a link between metabolic disorders and atherosclerosis. In this review, we summarize the anti-atherosclerosis effect and novel mechanisms underlying the function of TCF7L2 to elucidate its potential as an anti-atherosclerosis biomarker and provide a novel therapeutic target for cardiovascular diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
